声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议对于Biotech来说,现金流是生命线。随着国内创新药大环境的转暖,AH两地上市Biotech公司造血能力也进一步增强。据国投证券统计,在营业收入方面,国内Biotech创新药企业商业化步入正轨,进入加速放量阶段。一方面已上市产品放量开始加速,2025年...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议对于Biotech来说,现金流是生命线。随着国内创新药大环境的转暖,AH两地上市Biotech公司造血能力也进一步增强。据国投证券统计,在营业收入方面,国内Biotech创新药企业商业化步入正轨,进入加速放量阶段。一方面已上市产品放量开始加速,2025年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.